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Introduction: Nephrolithiasis still remains a too frequent and underappreciated cause of end 
stage renal disease (ESRD).
Methods and patients: Of the entire cohort of 7128 consecutive patients who started main-
tenance dialysis in our nephrology department between January 1992 and December 2006, a 
total of 45 patients (26 women, 19 men) had renal stone disease as the cause of ESRD. The type 
of nephrolithiasis was determined in 45 cases and etiology in 42. The treatment and evolution 
of stone disease and patient’s survival were studied.
Results: The overall proportion of nephrolithiasis related ESRD was 0.63%. The mean age 
was 48.4 years. Infection stones (struvite) accounted for 40%, calcium stones, 26.67% (primary 
hyperparathyroidism:15.56%; familial hypercalciuria: 4.44%, unknown etiology: 6.66%), pri-
mary hyperoxaluria type 1, 17.78% and uric acid lithiasis in 15.56% of cases.
The mean delay of the evolution of the stone renal disease to chronic renal failure was 85.8 months. 
The feminine gender, obesity and elevated alkaline phosphatases 128 IU/L were significantly 
correlated with fast evolution of ESRD. The median evolution to ESRD was 12 months. The 
normal body mass index (BMI), medical treatment of stone and primary hyperoxaluria type 1 
were correlated with fast evolution to ESRD.
All patients were treated by hemodialysis during a mean evolution of 60 months. Sixteen 
patients died. The patient's survival rate at 1, 3 and 5 years was 97.6, 92.8 and 69% respectively. 
Hypocalcemia, cardiopathy and normal calcium-phosphate product were significantly correlated 
with lower survival rate.
Conclusion: Severe forms of nephrolithiasis remain an underestimated cause of ESRD. These 
findings highlight the crucial importance of accurate stone analysis and metabolic evaluation to 
provide early diagnosis and efficient treatment for conditions leading to ESRD.
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Introduction
The contribution of nephrolithiasis related to end stage renal disease (ESRD) in patients 
requiring renal replacement therapy has never been specifically evaluated. Nephroli-
thiasis still remains a too frequent and underappreciated cause of ESRD and this is all 
the most unfortunate since such prognosis is now preventable in most cases.
Infection stones, especially when bilateral developing a stag horn configuration 
are universally considered the most frequent cause of urolithiasis associated ESRD.1,2 
Extensive stone development also has been observed with calcium-oxalate, uric acid 
or cystine stones and in patients with anatomic abnormalities of the urinary tract.3
In addition to the well known obstructive and infections mechanisms of kidney 
injury crystal deposition in the tubules and interstitium of both kidneys constitutes International Journal of Nephrology and Renovascular Disease 2010:3 22
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  compared using chi square. The patient’s survival rates 
were compared using the actuarial method and comparison 
was performed using logrank test. The level of statistical 
significance was at 5%.
Results
The overall proposition of nephrolithiasis related ESRD 
among the total number of incident ESRD cases was 0.63% 
(ie, 45 of 7128 patients). Annual incidence was 3. Of the 
45 patients, there were 19 men (42.22%) and 26 women 
(57.78%) with a gender ratio of 0.73.
The mean age of the patients was 48.4 ± 17.63 years 
(range of 17–80). The majority of patients (32) originated 
from the north and the north west of Tunisia, (74.11%); ie, 
20 (44.44%) and 12 (16.67%) respectively. Eight patients 
originated from the central Tunisia (17.78%) and 5 from 
the south (11.11%).
Eleven patients had family antecedents of urinary lithiasis 
(24.45%) and six of primary hyperparathyroidism type 1. 
Twenty four patients had hypertension (53.33%), six had 
diabetes (13.33%) and four cardiopathy (8.89%).
The Table 1 illustrates the discovering circumstances of 
nephrolithiasis. The diagnosis of nephrolithiasis stemmed from 
painful symptomatology, hematuria or urinary infection and 
was confirmed by radiology (x-ray–tomography–urography). 
Morphoconstitutional analysis, supplemented by biochemical 
and metabolic evaluation of nephrolithiasis, confirmed the 
nature and etiology of calculi. Tables 2 and 3 illustrate the 
composition and the etiologies of nephrolithiasis.
Thirty one patients were treated surgically: 15 had a 
  lombotomy with lithotomy; 10 a unilateral nephrectomy, 3 a 
percutaneous nephrolithotomy and 3 treated with extracorpo-
real lithotripsy. The 14 remaining patients were treated medi-
cally. The median of evolution of the nephrolithiasis from 
nephropathy to chronic renal failure (CRF) was 24 months 
another, often underappreciated mechanism of progressive 
renal failure.
The potential risk of degradation of renal function justi-
fies the etiological investigation of all lithiasis associated 
pathologies. Therefore calculus analysis of the crystalline 
phases and morphological characteristics is an important 
factor in the etiological diagnosis of the disease.
In the present study we reviewed the charts of all patients 
for whom urinary stone disease was recorded as the exclusive 
or preponderant cause of ESRD in the entire cohort of patients 
who started maintenance dialysis therapy at our nephrology 
department from 1992 to 2006. We analyzed: the frequency 
of nephrolithiasis associated ESRD; distribution of various 
types of nephrolithiasis; their respective cause; treatment; and 
evolution. We reviewed also patient survival rate at 1, 3 and 
5 years. These results were then compared to data contained 
in the literature.
Patients and methods
Of the entire cohort of 7128 consecutive patients who started 
maintenance dialysis therapy at our nephrology depart-
ment between January 1992 and December 2006, a total of   
45 patients (26 women, 19 men) had renal stone disease as 
the cause of ESRD and constitute the patients in this study. 
In all 45 patients urinary stone disease was the exclusive or 
preponderant cause of ESRD assessed by means of a detailed 
patient history, renal biopsy and exclusion of other possible 
causes of interstitial nephropathy and renal insufficiency. The 
cause of stone disease was identified on the basis of history, 
laboratory data and urinary crystal examination.
Stones that developed in patients who were on dialysis 
  therapy were not considered in our study. The Cockcroft 
and Gault equation was used in the assessment of creatinine 
clearance.
Creatinine clearance =
(140   age)  weight (kg)
Creatininemi
− ×
a a ( mol/L) µ
This product should be multiplied by 1.23 for men.   
A renal failure is defined by a creatinine clearance lower than 
80 mL/minute and the end stage is retained if the creatinine 
clearance is lower than 10 mL/minute.
The statistical analysis was made using the Stat View 
Software 5.0. Categorical variables were compared using 
the unpaired student’s T-test. Nominal variables were 
Table 1 Discovering circumstances of nephrolithiasis 
Discovering  
circumstances
Number of  
patients
Percentage % 
Renal colic 16 35.55
Fortuitous discovery (radiology) 8 17.78
Lithiasis Emission 5 11.11
Urinary infection 5 11.11
Macroscopic Hematuria 4 8.89
Kidney Failure 3 6.67
Others 4 8.89
Total 45 100International Journal of Nephrology and Renovascular Disease 2010:3 23
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Table 2 Composition of lithiasis and nature
Composition Number of patients Percentage %
Struvite 18 40
Calcium lithiasis 12 26.67
Oxalic lithiasis 8 17.77
Uric acid lithiasis 7 15.56
Total 45 100
Table 3 Etiologies of nephrolithiasis
Etiology  Number of  
patients
Percentage % 
Infectious lithiasis 18 40
Primary hyperparathyroidism 7 15.56
Familial hypercalciuria 2 4.44
Unknown calcic lithiasis etiology 3 6.66
Primary hyperoxaluria type 1 8 17.78
Uric acid lithiasis 7 15.56
Total 45 100
(range 1–408 months). The evolution to CRF was faster 
in men than women (68 versus 109 months, P = NS). The 
evolution of the condition in patients  originating from the 
center of Tunisia rather than those from north (35.1 versus 
124.8 months, P = NS) or North West (35.1 versus 72.7, 
P = NS). Patients with hypertension versus others without 
(59.1 versus 116.2 months P = 0.08) without any statistically 
signification. The condition was also significantly faster in 
the event of diabetes (19.3 versus 96 months, P = NS) or 
cardiopathy (18.75 versus 92.3, P = NS). Obesity defined 
by a body mass index (BMI)  30 kg/m2 was correlated 
with a faster evolution to CRF (14.8 versus 99.7 months, 
P = 0.03).
The etiology of nephrolithiasis had no impact on this 
evolution. Surgical treatment slowed down the evolution of 
CRF compared to medical treatment (97 versus 61 months) 
without any statistically significance.
Alkaline phosphatases higher than 128 IU/L were 
  significantly correlated with a faster evolution to CRF than 
those lower than 128 IU/L (57 versus 142.9 months, P = 0.011) 
No correlation was found with the other phosphocalcic param-
eters (calcemia – phosphate, calcium – phosphate product 
and parathormone).
The final stage of CRF was reached after a median 
  evolution of 12 months (range 1–156 months). The age, 
gender and geographic origin had no significant impact 
on the evolution to ESRD. Obesity was significantly cor-
related to the evolution to ESRD (71 versus 18 months, 
P = 0.015).
The patients having a parathyroid hormone (PTH) 
between 150 and 300 pg/mL evolved more quickly to 
ESRD than patients having secondary hyperparathyroidism 
(19.66 versus 36.6 months, P = NS).
The nephrolithiasis etiology had no impact on the 
  evolution to ESRD, nevertheless patients having primary 
hyperoxaluria type 1 evolved more quickly to ESRD than 
those having infectious (15.45 versus 31.7 months, P = NS) or 
calcic nephrolithiasis (15.45 versus 41.3 months, P = NS).
The medical treatment of the lithiasis was significantly 
correlated to a faster evolution to ESRD compared to 
  urological treatment (8.75 versus 53.2 months, P = 0.04). 
All patients were treated by hemodialysis. The median 
duration of dialysis was 59 months (range 1–169 months). 
Osteoarticular complications occurred in 91.11% of patients 
(secondary hyperparathyroidism = 55.56% and adynamic 
bone disease in 35.56% of patients) and cardiovascular in 
66.67% (cardiac failure: 22.22%, coronaropathy 20% and 
heartbeat rate disorders 22.3%).
Sixteen patients died. The Table 4 illustrates the causes 
of death. The patient’s survival rate at 1, 2, 3 and 5 years 
was: 97.6%; 95%; 92.8%; and 69% respectively and this was 
96%; 95.2%; 90%; and 71% for all dialyzed patients. Age, 
gender, geographic origin, hypertension, BMI had no impact 
on patient’s survival or nephrolithiasis etiology. Patient sur-
vival at 5 years was significantly combined with cardiopathy 
(33% versus 72%, P = 0.06), hypocalcemia (56% versus 
100%. P = 0.014), normal calcium phosphorus product (53% 
  versus 92% P = 0.0084). The other phosphocalcic parameters 
had not any impact on patient survival. The faster evolution 
to the ESRD (31.5 months) was significantly correlated 
Table 4 The causes of death
Cause of  
death
Number of  
patients
Percentage (%) 
Sudden death 6 37.5
Septic shock 4 25
Acute pulmonary Edema 1 6.25
Hypokalemia 1 6.25
Cachexia 1 6.25
Stroke 1 6.25
Myocardial infarction 1 6.25
Tuberculous spondylodiscitis 1 6.25
Total 16 100International Journal of Nephrology and Renovascular Disease 2010:3 24
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with longer survival at 7 years compared to slower evolution 
(31.5 months).
Discussion
End stage renal disease caused by urinary stone disease, 
although accounting for a limited proportion of cases, still 
remains a problem that should not be overlooked.
The principal mechanisms involved in the development 
of renal failure in patients with nephrolithiasis were recurrent 
stone formation, obstruction of the excretory tract and exten-
sive crystal deposition in the renal parenchyma. Irreversible 
renal impairment was observed essentially in patients with 
a delayed diagnosis, suboptimal urological and medical 
management, or intrinsically severe forms of stone disease.4,5 
Severe forms of nephrolithiasis remain an underestimated 
cause of potentially avoidable ESRD and the need renal 
replacement therapy.6
In our experience, nephrolithiasis related ESRD 
  contributed 0.63% to the total series of patients who 
started maintenance dialysis therapy at our department 
of nephrology during a 15 year period. These figures are 
in agreement with those extracted from recent the United 
States Renal Data System data. Among 228,332 white 
patients who started renal replacement therapy in the US 
from 1993 to 1997, a total of 1.5% were categorized as 
having “nephrolithiasis, obstruction, gouty “ as the pri-
mary renal disease, thus leading to an estimated incidence 
of 2.9 patients/year. Paul Jungers and colleagues have 
reported that the overall proportion of nephrolithiasis 
related ESRD was 3.2%.6 Another estimation can be 
extracted from a prospective epidemiological inquiry 
conducted at all nephrology and dialysis units in the Ile de 
France area, which has a total population of 10.7 million 
inhabitants. Of 1060 adult patients who started maintenance 
dialysis therapy in 1998, nephrolithiasis was recorded as the 
cause of ESRD in 1.8% of cases.7 In a cohort of 171 patients 
with severe idiopathic calcium stone disease reported by 
Marangella and colleagues 18% had mild renal insufficiency 
but no patients reached ESRD during a mean follow up of 
3.5 years.8 Of 2000 consecutive unselected stone formers 
reported by Gupta and colleagues only 33 patients (1.7%) 
had mild to moderate renal failure.9 A very low frequency 
of progressive renal failure was reported in other studies. 
Of 3266 patients with nephrolithiasis reported recently 
by Worcester and colleagues none developed ESRD and 
there was no significant decline in creatinine clearance 
between the first and the last visit.2 Jungers reported that 
the frequency of nephrolithiasis related ESRD significantly 
decreased with time; from an average proportion of 4.7% 
from 1989 to 1991 to 2.2% from 1998 to 2000.6
In our study, the rate of ESRD, due to nephrolithiasis, 
was the prerogative of the fifty years old adult patients with 
female prevalence. In a Moroccan study including 183 
patients, Oussama and colleagues reported that the average 
age was 60 years with clear male prevalence.10 Coe and 
colleagues found the similar results.11 The potential risk of 
degradation of renal function highlights the crucial impor-
tance of accurate stone analysis and metabolic evaluation to 
provide early diagnosis and the correct therapy for conditions 
that may lead to ESRD.
In our study, morphoconstitutional analysis of calculi 
from 45 patients showed that struvite was the main com-
ponent in 40% of cases. In all these patients, disease onset 
occurred a long time ago, before the modern era of urological 
treatment. This cause of stones has been reported in other 
studies: Jungers in 36%6 and Gupta in 64% of cases.9
However many authors reported that the frequency of this 
cause will decrease in the future because of earlier diagnosis 
and easier urological management.12 Struvite accounted for 
15.3% of nephrolithiasis among 183 patients for Oussama 
and colleagues.10 The female prevalence noted in our series 
was also found by Gupta9 although not by Oussama.10
In children, Daudon and colleagues noted that struvite 
frequency was 9.9% of cases.13 Although responsible for 
ESRD in nearly 26.67% of our patients, calcium stones 
appear to be an infrequent cause of ESRD compared with the 
very large number of calcium stone formers. Its frequency 
was 26.7% for Jungers and even higher for Oussama in 
58.5% of cases.6,10
In our experience, such an outcome is mainly caused by 
late diagnosis in patients with primary hyperparathyroidism 
(58.83%) and idiopathic hypercalciuria (16.66%) resulting 
in multiple stone episodes; with the aggravating influence of 
recurrent urinary tract infection in several patients.
Among 12 calcium stones reported by Jungers, heavy 
hypercalciuria was present in 33% of cases, primary hyper-
parathyroidism in 16.66% and medullary sponge kidney in 
41.67% of cases.6 In our study the etiology was not identified 
in 6.66% of cases. This frequency was much less than that 
of Gupta with 59% of cases.9
Uric acid nephrolithiasis accounted for 15.56% of cases 
in our study; however in western literature, it represented 
by 7.2% to 15.3% of cases.14–16 This figure was 17.8% for 
Jungers and 18% for Oussama.6,10 It does seem that this type 
of calculi is more frequent in North Africa than in Europe or 
US, suggesting the influence of nutritional factors.10International Journal of Nephrology and Renovascular Disease 2010:3 25
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There was a male prevalence in our series and also for 
Oussama.10 Primary hyperoxaluria type 1 (PH1) is frequently 
misdiagnosed, especially when urinary stones manifest first 
in adult patients or if early symptoms are misinterpreted.6 
It accounted for 17.78% of nephrolithiasis in our study. This 
frequency was largely higher than that of Jungers.6 A very 
low frequency of progressive renal failure especially ESRD 
was reported.
Of 3266 patients with nephrolithiasis reported by 
Worcester and colleagues none developed ESRD and there 
was no significant decline in creatinine clearance between 
the first and the last visit (2). In our experience, the evolution 
of nephrolithiasis nephropathy to chronic renal failure (CRF) 
was paradoxically very fast, with a median of 24 months. 
This figure was of 7 years for Teichmann17 and 4 years 
for Coe.11 In agreement with the results of Giovanni,18 the 
median evolution was shorter among women. Hyperten-
sion and obesity were significantly correlated with a faster 
evolution to CRF.
There was no significant correlation found with calcemia, 
phosphatemia, calcium phosphate product, parathormone and 
hemoglobin. However alkaline phosphatases levels superior 
to 128 IU/L were correlated with faster evolution to CRF.
In agreement with Steven’s results.19 urological treatment 
allowed the slackening of the evolution to CRF compared 
to the symptomatic treatment in our series. The end stage of 
renal insufficiency was reached after a median of 12 months 
in our patients. Singh and colleagues reported that 14 patients 
among 20 with nephrolithiasis evolved to ESRD in a time 
lower that one year.20
Contrary to the age, gender and geographical origin which 
had no impact on the evolution to ESRD, obesity was signifi-
cantly associated with a slower evolution. This result was also 
reported by Daniel.21 Secondary hyperparathyroidism and 
urological treatment were associated with slower evolution 
to ESRD. In the experience of Teichmann, all patients treated 
medically suffered a deterioration in their renal function 
against only 28% of surgically treated patients.17 The etiology 
of nephrolithiasis had no impact on the evolution to ESRD 
among our patients, nevertheless those having primary hyp-
eroxaluria type 1 (PHA1) developed faster ESRD than those 
having a struvite or a primary hyperparathyroidism.
All our patients were treated by hemodialysis during a 
median evolution of 60 months. Sixteen patients died because 
of cardiovascular and infectious complications. The patient’s 
survival rate at 1, 2, 3 and 5 years was respectively 97.6%, 
95%, 92.8% and 69%, which was comparable with the sur-
vival rate of the totality of dialyzed patients.
No data concerning patient’s survival was found in the 
literature. The age, gender and geographical origin had 
no impact on the patient’s survival rate. O’Connor and 
colleagues showed that advanced age is a risk factor of 
renal function deterioration and mortality among patients 
having nephrolithiasis related ESRD.22 Hypertension had no 
impact on the patient’s survival rate, whereas cardiopathy 
was associated with lower rate at 5 years.
Contrary to the results of Daniel21 we did not find any 
statistical correlation between the BMI and the patient sur-
vival rate. The nephrolithiasis etiology also had no impact 
on patient survival.
The fast evolution to ESRD (31.5 months) was 
significantly associated with a better survival compared 
to the slow evolution (31.5 months). The evolution to 
CRF can be prevented with an early etiologic diagnosis 
of nephrolithiasis and an appropriate treatment. However 
severe forms of renal stone disease are much less frequent 
that the common benign forms. This must be kept in mind 
in view of the disastrous consequences that may result 
from delayed or improper diagnosis and treatment.23 In this 
regard, adequate analysis of stones and/or crystalluria 
together with proper metabolic evaluation are of crucial 
diagnosis value. They should never be neglected, especially 
in patients with the onset of nephrolithiasis in childhood, 
severely recurrent stones, nephrocalcinosis or incipient 
renal insufficiency as noted by Gambaro and colleagues.3 
To this end the patient should be involved in the care of 
the nephrolithiasis.
The installation of medical software containing different 
clinical, biological and morphologic data accessible to all 
physicians from all specialties allows better coordination of 
the patient’s care.
Conclusion
Nephrolithiasis remains the cause of potentially avoidable 
ESRD in too many patients despite recent major advances 
in the diagnosis and management of patients forming stones.
These findings highlight the crucial importance of accurate 
stone analysis and metabolic evaluation to provide early 
diagnosis and proper therapy for a condition that may lead 
to ESRD through recurrent stone formation and/or crystal 
infiltration. ESRD and renal replacement therapy should 
be prevented in the future in most patients with renal stone 
disease.
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